NDAORALTABLET
Approved
Oct 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
DAYPRO (oxaprozin) by Pfizer is cyclooxygenase inhibitors [moa]. First approved in 1992.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAYPRO (oxaprozin) is an oral nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain. It is a small-molecule tablet approved in 1992 for management of inflammatory and rheumatologic conditions. The drug is currently approaching loss of exclusivity with minimal patent protection remaining.
$0.035BPart D
LOE ApproachingDeclining
Declining commercial trajectory with minimal team expansion; roles focus on defense against generics and efficient portfolio management rather than growth initiatives.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Drug-drug Interaction Study of FYU-981 and Oxaprozin
Started Nov 2017
12 enrolled
Healthy
Career Relevance
Working on DAYPRO offers limited career acceleration due to LOE proximity and market maturity; roles are defensive and operationally focused rather than strategically expansive. Professionals should view DAYPRO assignments as portfolio management experience or stepping stones to growth-stage products within Pfizer's portfolio.
Brand Manager (Legacy)
Worked on DAYPRO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.